Extravasation of an antibody‐drug conjugate: A case report of epidermal necrosis after trastuzumab‐emtansine extravasation
| Autor: | Teun Teunis, Mariette J Agterof, Bastiaan T.G.M. Sallevelt, Marcel P H van den Broek |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Antibody-drug conjugate medicine.medical_specialty medicine.medical_treatment Case Report Case Reports Residual hyperpigmentation chemotherapy 030226 pharmacology & pharmacy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Medicine Pharmacology (medical) 030212 general & internal medicine Pharmacology Chemotherapy trastuzumab‐emtansine business.industry epidermal necrosis Extravasation chemistry Epidermal necrosis Trastuzumab emtansine Toxicity oncology business extravasation Conjugate antibody‐drug conjugate |
| Zdroj: | Journal of Clinical Pharmacy and Therapeutics |
| ISSN: | 1365-2710 0269-4727 |
| Popis: | What is known and objective Trastuzumab‐emtansine is an antibody‐drug conjugate developed to decrease off‐target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate. Case summary We report on a 51‐year‐old woman who developed epidermal necrosis after extravasation of trastuzumab‐emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation. What is new and conclusion We describe the course of a case of severe toxicity following trastuzumab‐emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation. This report describes the course of severe skin toxicity following trastuzumab‐emtansine extravastion and provides treatment recommendations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |